ABSTRACT
Objective We sought to compare the costs of a nighttime pre-emergency pediatric telemedicine and medication delivery service (TMDS) per disability-adjusted life year (DALY) averted to the costs of hospital emergency medicine (HEM) per DALY averted from a societal perspective.
Methods We studied a nighttime pediatric TMDS and HEM in a semi-urban and rural region of Haiti. Costs of the 2 services were enumerated to represent the financial investments of both providers and patients. DALYs averted were calculated to represent the ‘years lives lost’ (YLL) and ‘years lost to disability’ (YLD) from diarrheal, respiratory, and skin (bacterial and scabies etiologies) disease among children from zero to 9 years old. The incremental cost-effectiveness ratio (ICER) was estimated and compared to the per-capita gross domestic product (GDP) of Haiti ($1,177). Cost-effectiveness was defined as an ICER less than 3 times the per-capita GDP of Haiti ($3,531). Univariate sensitivity analysis was performed to evaluate how uncertainty of individual parameter estimates (utilization rates, costs, lost wages, discounting factor) affected the ICER.
Results The total costs of the nighttime TMDS and HEM to society were $285,931.72 per year and $89,335.41 per year, respectively. The DALYs averted by the TMDS and HEM were 199.76 and 22.37, respectively. Through sensitivity analyses, the ICER of the TMDS ranged from $791.43 to $1,593.35.
Conclusion A nighttime pediatric TMDS is a cost-effective alternative to HEM for pre-emergency pediatric care in semi-urban and rural regions in Haiti, and possibly in similar lower-middle income countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health grants to EJN [DP5OD019893] and internal support from the Emerging Pathogens Institute (EJN), the Departments of Pediatrics (EJN), the Department of Environmental and Global Health (EJN), and the Department of Emergency Medicine (KEF/TKB) at the University of Florida.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approvals were obtained from the Comite National de Bioethique (National Bioethics Committee of Haiti) and the University of Florida Institutional Review Board for participants in INACT-1 (1718-35; IRB201703246) and INACT-2 (1920-42; IRB201802920). For both studies, participants provided written informed consent/assent. For INACT-2, a waiver of documentation of written consent was obtained for those without a household delivery.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
flahertyl{at}ufl.edu
mklarman{at}ufl.edu
ycajusma{at}ufl.edu
jschon{at}wm.edu
lerbymd{at}gmail.com
madsenbeau{at}phhp.ufl.edu
barilchantale56{at}gmail.com
t.becker{at}ufl.edu
Data Availability
All pertinent data is included in the manuscript.
